Skip to main content

Advertisement

SpringerLink
Log in

Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

This study focuses on investigating the expression correlation of vimentin, survivin and p53 in clear cell renal cell carcinoma (ccRCC) and the clinical significance.

Methods

The mRNA and protein expression levels of the vimentin, survivin and p53 were determined in ccRCC and adjacent normal renal tissues, using quantitative real-time-polymerase chain reaction (qRT-PCR) and Western blot. We detected the expression and localization of vimentin, survivin and p53 protein in ccRCC by immunohistochemistrical SP method and analyzed the relationships among clinical pathologic parameters and patient prognosis.

Results

The expression of vimentin and survivin was significantly increased in ccRCC compared with adjacent normal renal tissues, which were positively correlated with the pathological grade and clinical stage (P < 0.05). p53 was highly expressed in ccRCC compared with normal tissues (P < 0.05), which was not positively correlated with the pathological grade and clinical stage (P > 0.05). Furthermore, univariate and multivariate analysis showed that high expression levels of vimentin and survivin were independent prognostic indicators for ccRCC. The levels of vimentin and survivin were positively correlated in ccRCC (r = 0.428, P < 0.01).

Conclusions

Reliable basis about biological behavior and prognosis judgments of ccRCC can be provided by combining detection of vimentin and survivin. Foundation and new ideas for gene therapy of ccRCC may be provided by further studying the relationship among vimentin, survivin and p53 in ccRCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119–32.

    Article  CAS  PubMed  Google Scholar 

  2. Klatte T, Pantuck AJ, Kleid MD, Belldegrun AS. Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. Rev Urol. 2007;9:47–56.

    PubMed Central  PubMed  Google Scholar 

  3. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477–90.

    Article  CAS  PubMed  Google Scholar 

  4. Schopferer M, Bär H, Hochstein B, Sharma S, Mücke N, Herrmann H, et al. Desmin and vimentin intermediate filament networks: their viscoelastic properties investigated by mechanical rheometry. J Mol Biol. 2009;388:133–43.

    Article  CAS  PubMed  Google Scholar 

  5. Shirahata A, Sakata M, Sakuraba K, Goto T, Mizukami H, Saito M, et al. Vimentin methylation as a marker for advanced colorectal carcinoma. Anticancer Res. 2009;29:279–81.

    CAS  PubMed  Google Scholar 

  6. Moustakas A, Heldin CH. Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98:1512–20.

    Article  CAS  PubMed  Google Scholar 

  7. Perlson E, Michaelevski I, Kowalsman N, Ben-Yaakov K, Shaked M, Seger R, et al. Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase. J Mol Biol. 2006;364:938–44.

    Article  CAS  PubMed  Google Scholar 

  8. Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol. 2007;9:1000–4.

    Article  CAS  PubMed  Google Scholar 

  9. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.

    Article  CAS  PubMed  Google Scholar 

  10. Chang L, Goldman RD. Intermediate filaments mediate cytoskeletal crosstalk. Nat Rev Mol Cell Biol. 2004;5:601–13.

    Article  CAS  PubMed  Google Scholar 

  11. Dean EJ, Ranson M, Blackhall F, Dive C. X-linked inhibitor of apoptosis protein as a therapeutic target. Expert Opin Ther Targets. 2007;11:1459–71.

    Article  CAS  PubMed  Google Scholar 

  12. Oto OA, Paydas S, Tanriverdi K, Seydaoglu G, Yavuz S, Disel U. Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literature. Leuk Res. 2007;31:1495–501.

    Article  CAS  PubMed  Google Scholar 

  13. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010;2:a001107.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther. 2011;18:2–11.

    Article  CAS  PubMed  Google Scholar 

  15. Vousden KN, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8:275–83.

    Article  CAS  PubMed  Google Scholar 

  16. Yang X, Wang J, Liu C, Grizzle WE, Yu S, Zhang S, et al. Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts. Am J Pathol. 2005;167:705–19.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science. 1991;253:49–53.

    Article  CAS  PubMed  Google Scholar 

  18. Levine AJ, Perry ME, Chang A, Silver A, Dittmer D, Wu M, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer. 1994;69:409–16.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Mohammed A, Shergill I, Little B. Management of metastatic renal cell carcinoma: current trends. Expert Rev Mol Diagn. 2009;9:75–83.

    Article  PubMed  Google Scholar 

  20. Liu T, Zhang X, Shang M, Zhang Y, Xia B, Niu M, et al. Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal like breast cancer. J Surg Oncol. 2013;107:188–94.

    Article  CAS  PubMed  Google Scholar 

  21. Yao X, Wang X, Wang Z, Dai L, Zhang G, Yan Q, et al. Clinicopathological and prognostic significance of epithelial mesencymal transition-related protein expression in intrahepatic cholangiocarcinoma. Onco Targets Ther. 2012;5:255–61.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer. 2008;99:1467–83.

    Article  Google Scholar 

  23. Zhao Y, Yan Q, Long X, Chen X, Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct. 2008;26:571–7.

    Article  CAS  PubMed  Google Scholar 

  24. Hwa JS, Park HJ, Jung JH, Kam SC, Park HC, Kim CW, et al. Identification of proteins differentially exrpressed in the conventional renal cell carcinoma by proteomic analysis. J Korean Med Sci. 2005;20:450–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Williams AA, Higgins JP, Zhao H, Ljunberg B, Brooks JD. CD9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol. 2009;9:9.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Hsu KF, Lin CK, Yu CP, Tzao C, Lee SC, Lee YY, et al. Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis Esophagus. 2009;22:402–8.

    Article  PubMed  Google Scholar 

  27. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109:1106–13.

    Article  CAS  PubMed  Google Scholar 

  28. Wang GC, Hsieh PS, Hsu HH, Sun GH, Nieh S, Yu CP, et al. Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness. World J Urol. 2009;27:557–63.

    Article  CAS  PubMed  Google Scholar 

  29. Andersen MH, Svane IM, Becker JC, Straten PT. The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007;13:5991–4.

    Article  CAS  PubMed  Google Scholar 

  30. Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10:188–93.

    Article  PubMed  Google Scholar 

  31. Hsu YF, Sheu JR, Lin CH, Yang DS, Hsiao G, Ou G, et al. Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochim Biophys Acta. 2012;1820:104–15.

    Article  CAS  PubMed  Google Scholar 

  32. Masuda A, Kamai T, Abe H, Arai K, Yoshida K. Is Stat3 and/or p53 mRNA expression a prognostic marker for renal cell carcinoma? Biomed Res. 2009;30:171–6.

    Article  CAS  PubMed  Google Scholar 

  33. Zubac DP, Bostad L, Kihl B, Seidal T, Wentzel-Larsen T, Haukaas SA. The expression of thrombospondin-1 and p53 in clear cell renal cell carcinoma: its relationship to angiogenesis, cell proliferation and cancer specific survival. J Urol. 2009;182:2144–9.

    Article  PubMed  Google Scholar 

  34. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 2002;21:2613–22.

    Article  CAS  PubMed  Google Scholar 

  35. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277:3247–57.

    Article  CAS  PubMed  Google Scholar 

  36. Lynch CJ, Milner J. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene. 2006;25:3463–70.

    Article  CAS  PubMed  Google Scholar 

  37. Vegran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. Distinct expression of survivin splice vaiants in breast carcinomas. Int J Oncol. 2005;27:1151–7.

    CAS  PubMed  Google Scholar 

  38. Kar R, Sen S, Singh A, Sharma H, Kumar S, Gupta SD, et al. Role of apoptotic regulators in human epithelial ovarian cancer. Cancer Biol Ther. 2007;6:1101–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by Grants from Program for Science & Technology Innovation Talents in Universities of Henan Province (#13HASTIT025) to SQL. The authors thank all the members in the laboratory when this work was carried out. The experiments complied with the current laws of China.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Urology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471003, People’s Republic of China

    Z.-G. Shi, Z.-J. Li, X.-J. Zhu, P. Xu & G. Liu

  2. Molecular Medicine Key Laboratory of Liver Injury and Repair, Medical College, Henan University of Science and Technology, Luoyang, 471003, People’s Republic of China

    S.-Q. Li

Authors
  1. Z.-G. Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S.-Q. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z.-J. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X.-J. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z.-J. Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shi, ZG., Li, SQ., Li, ZJ. et al. Expression of vimentin and survivin in clear cell renal cell carcinoma and correlation with p53. Clin Transl Oncol 17, 65–73 (2015). https://doi.org/10.1007/s12094-014-1199-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-014-1199-1

Keywords

Search

Navigation